Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 4/20 | 0.64 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 5/20 | 0.46 |
| ▸ | JUN | P05412 | 3/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498295 | 0.92 | MTOR (0.62) | MAPK10SMG1MTORJAK2CA12 | |
| SCHEMBL1632623 | 0.90 | MAPK10 (0.53) | MAPK10SMG1MTORJAK2LRRK2 | |
| SCHEMBL1633214 | 0.86 | MAPK10 (0.50) | MAPK10SMG1MTORJAK2EGFR | |
| SCHEMBL1632821 | 0.85 | MTOR (0.49) | MAPK10SMG1MTORJAK2LRRK2 | |
| SCHEMBL1633437 | 0.84 | JAK2 (0.54) | MAPK10SMG1MTORJAK2LRRK2 | |
| SCHEMBL1631208 | 0.84 | MAPK10 (0.47) | MAPK10SMG1MTORJAK2EGFR | |
| SCHEMBL1632234 | 0.84 | MAPK10 (0.47) | MAPK10SMG1MTORJAK2EGFR | |
| SCHEMBL1631212 | 0.84 | MAPK10 (0.47) | MAPK10SMG1MTORJAK2EGFR | |
| SCHEMBL1634662 | 0.83 | MAPK10 (0.56) | MAPK10SMG1MTORJAK2LRRK2 | |
| SCHEMBL1633187 | 0.82 | MTOR (0.60) | MAPK10SMG1MTORJAK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAPK10 402/4885SMG1 1001/4885MTOR 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.